Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell disease

3 Jun 2024

Abstract excerpt

Hydroxyurea (HU) is the most common drug therapy for sickle cell disease (SCD). The clinical benefits of HU derive from its upregulation of fetal hemoglobin (HbF), which reduces aggregation of the mutated sickle hemoglobin protein (HbS) and reduces SCD symptoms and complications. However, some individuals do not respond to HU, or stop responding over time. Unfortunately, current understanding of the mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38831675
DOI: 10.1111/ejh.14247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell diseasePMID 38831675Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Semantic proximity Read ↗

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Semantic proximity Read ↗

Recent Advances in the Treatment of Sickle Cell DiseaseSemantic proximity Read ↗

Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA OptionSemantic proximity Read ↗

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell DiseaseSemantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Hydroxyurea Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach.Semantic proximity Read ↗

Single Nucleotide Polymorphisms in XMN1-HBG2, HBS1L-MYB, and BCL11A and Their Relation to High Fetal Hemoglobin Levels That Alleviate AnemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.